ALKERMES traded at $34.84 this Thursday April 2nd, decreasing $0.21 or 0.60 percent since the previous trading session. Looking back, over the last four weeks, ALKERMES lost 19.32 percent. Over the last 12 months, its price rose by 10.04 percent. Looking ahead, we forecast ALKERMES to be priced at 33.76 by the end of this quarter and at 30.72 in one year, according to Trading Economics global macro models projections and analysts expectations.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.